BeOne Medicines (NASDAQ:ONC) Director Sells $898,105.00 in Stock

Key Points

• Corazon Sanders, a director at BeOne Medicines, sold 2,665 shares of the company's stock for a total of $898,105 on September 5th.
• BeOne Medicines recently reported earnings of $0.84 per share, exceeding analyst expectations of $0.48, along with revenue of $1.32 billion.
• Seven analysts currently rate BeOne Medicines as a Buy, with an average price target of $330.89.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) Director Corazon (Corsee) D. Sanders sold 2,665 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $337.00, for a total transaction of $898,105.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

BeOne Medicines Trading Down 3.4%

NASDAQ ONC traded down $11.33 during trading hours on Friday, reaching $324.34. The company's stock had a trading volume of 274,640 shares, compared to its average volume of 351,780. The firm has a fifty day simple moving average of $300.22 and a 200-day simple moving average of $265.75. The stock has a market cap of $35.55 billion, a P/E ratio of -187.48 and a beta of 0.21. BeOne Medicines Ltd. - Sponsored ADR has a 52 week low of $170.99 and a 52 week high of $351.27. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The business had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. Equities analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ONC shares. Guggenheim raised their price target on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. Morgan Stanley lifted their price objective on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research note on Friday, June 27th. Royal Bank Of Canada lifted their price objective on shares of BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. lifted their price objective on shares of BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Finally, Wall Street Zen lowered shares of BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Seven equities research analysts have rated the stock with a Buy rating, According to MarketBeat, BeOne Medicines has a consensus rating of "Buy" and an average price target of $330.89.

Institutional Trading of BeOne Medicines

Several institutional investors have recently made changes to their positions in the company. Primecap Management Co. CA bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $1,231,720,000. Temasek Holdings Private Ltd bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $244,603,000. Marshall Wace LLP bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $113,190,000. Baird Financial Group Inc. bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $73,347,000. Institutional investors own 48.55% of the company's stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.